Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD) will be announcing its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amicus Therapeutics has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. The firm’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Trading Up 1.7 %

Shares of Amicus Therapeutics stock traded up $0.19 during trading on Tuesday, reaching $11.52. 621,157 shares of the company were exchanged, compared to its average volume of 2,701,213. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The business has a 50-day moving average price of $11.14 and a 200-day moving average price of $10.59. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of -29.05 and a beta of 0.68.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 22,500 shares of company stock worth $253,275 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on FOLD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Bank of America lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 31st. Morgan Stanley reduced their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.13.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.